Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Aurinia Pharmaceuticals Inc
Interest Income Expense
Aurinia Pharmaceuticals Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Interest Income Expense
$13.7m
|
CAGR 3-Years
157%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
34%
|
|
Zymeworks Inc
NYSE:ZYME
|
Interest Income Expense
$18.5m
|
CAGR 3-Years
36%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
Theratechnologies Inc
TSX:TH
|
Interest Income Expense
-$8.1m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Interest Income Expense
$13.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Interest Income Expense
$4.1m
|
CAGR 3-Years
131%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Spectral Medical Inc
TSX:EDT
|
Interest Income Expense
-CA$3.2m
|
CAGR 3-Years
-373%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Aurinia Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
13.7m
USD
Based on the financial report for Mar 31, 2024, Aurinia Pharmaceuticals Inc's Interest Income Expense amounts to 13.7m USD.
What is Aurinia Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
34%
Over the last year, the Interest Income Expense growth was 58%. The average annual Interest Income Expense growth rates for Aurinia Pharmaceuticals Inc have been 157% over the past three years , and 34% over the past ten years .